---
title: "Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Guidelines questions"
description: "Guidelines questions on Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection, each answered with verbatim quotes from the manufacturer's US website for healthcare professionals or documents it links. Topics: Adherence. Questions: Is Biktarvy a recommended HIV regimen in the DHHS guidelines? Biktarvy for people with HIV adherence challenges: what do DHHS guidelines recommend? 2 questions quoted from 2 sources."
canonical: "https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/guidelines"
published: "2026-11-12T22:05:36-05:00"
modified: "2026-11-14T15:19:23-05:00"
---

# Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide) in HIV-1 infection: Guidelines questions

Manufacturer: Gilead Sciences, Inc.  
Prescribing information: [Biktarvy](https://www.gilead.com/~/media/files/pdfs/medicines/hiv/biktarvy/biktarvy_pi.pdf)

## Guidelines

<a id="biktarvy-dhhs-guidelines"></a>

### Is Biktarvy a recommended HIV regimen in the DHHS guidelines?

> “BIKTARVY is DHHS guidelines–recommended<sup>17,18</sup>
> As an initial regimen for most people living with HIV
> In virologically suppressed people with M184V/I resistance mutation (BIII)*
> As a preferred initial regimen for children ≥2 years old (≥14 kg)”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/clinical-trial-experience#:~:text=BIKTARVY%20is%20DHHS,%E2%89%A52%20years%20old%20%28%E2%89%A514%20kg%29)

> “*Rating of recommendation: B=Moderate. Rating of evidence: III=Expert opinion.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/clinical-trial-experience#:~:text=%2ARating%20of%20recommendation%3A%20B%3DModerate.%20Rating%20of%20evidence%3A%20III%3DExpert%20opinion.)

## Adherence

<a id="biktarvy-adherence"></a>

### Biktarvy for people with HIV adherence challenges: what do DHHS guidelines recommend?

> “People with HIV who have ART adherence challenges should be placed
> on regimens with high genetic barriers to resistance.* Side effects, out-of-pocket costs, convenience, and individual preferences should also be
> considered.<sup>1</sup>
>
> *Please see DHHS guidelines for specific recommended antiretrovirals.”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/treatment-considerations/adherence-considerations#:~:text=People%20with%20HIV%20who%20have,guidelines%20for%20specific%20recommended%20antiretrovirals.)

> “BIKTARVY is DHHS guidelines–recommended for PWH with adherence challenges<sup>17</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/clinical-trial-experience#:~:text=BIKTARVY%20is%20DHHS%20guidelines%E2%80%93recommended%20for%20PWH%20with%20adherence)

> “Other considerations include side effects, out-of-pocket costs, convenience, and patient preferences<sup>17</sup>”

Source: [BIKTARVY: BIKTARVY(bictegravir) - For Healthcare Professionals, captured 2026-11-12](https://www.biktarvyhcp.com/efficacy-resistance/clinical-trial-experience#:~:text=Other%20considerations%20include%20side%20effects%2C%20out%2Dof%2Dpocket%20costs%2C%20convenience%2C%20and%20patient)

Note: The DHHS statement quoted from the adherence page recommends regimens with high genetic barriers to resistance as a group and refers readers to the guidelines for the specific antiretrovirals. The statement that Biktarvy is DHHS guidelines–recommended for people with adherence challenges is the manufacturer's.

## Related pages
- [Medical information: Biktarvy (bictegravir, emtricitabine, and tenofovir alafenamide): HIV-1 infection](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection)
- [Indication](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/indication)
- [Pharmacology](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/pharmacology)
- [Clinical trials](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/clinical-trials)
- [Safety](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/safety)
- [Specific populations](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/specific-populations)
- [Drug interactions](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/drug-interactions)
- [Dosing and administration](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/dosing-and-administration)
- [Storage and supply](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/storage-and-supply)
- [Access and coverage](https://www.evicenter.com/medical-information/biktarvy--hiv-1-infection/access-and-coverage)
